Get started
Author

Katerin Rojas

Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors
2020 · Ana Alcaraz-Sanabria, Mariona Baliu-Piqué, et al. · Frontiers in Oncology · 43
PDF
In silico transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer
2021 · Katerin Rojas, Mariona Baliu-Piqué, et al. · Cellular Oncology · 27
Genomic landscape and immune-related gene expression profiling of epithelial ovarian cancer after neoadjuvant chemotherapy
2022 · I. Lodewijk, A. Bernardini, et al. · npj Precision Oncology · 26
PDF
Proteomics characterisation of central nervous system metastasis biomarkers in triple negative breast cancer
2019 · Katerin L Rojas, Lucía Trilla-Fuertes, et al. · ecancermedicalscience · 17
PDF
Association between mammographic features and response to neoadjuvant chemotherapy in locally advanced breast carcinoma
2014 · Carlos A Castaneda, Raymundo Flores, et al. · Hematology/Oncology and Stem Cell Therapy · 15
PDF
679 Characterization of tumor specific CD8+ T cell responses in patients with recurrent/metastatic HPV16-positive head and neck cancer receiving HB-200 monotherapy as second or later line treatment in a phase 1 study
2023 · Alan L Ho, Alexander T Pearson, et al. · Journal for ImmunoTherapy of Cancer · 6
PDF
Características clínicas y toxicidad del tratamiento de tuberculosis en pacientes con cáncer
2015 · Luis Cuéllar, Carlos A. Castañeda, et al. · Revista Peruana de Medicina Experimental y Salud Pública · 5
PDF
A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al. · Clinical Cancer Research · 3
PDF
Abstract CT109: First-in-class first-in-human phase 1 trial and translational study of the mono(ADP-ribose) polymerase-7 (PARP7) inhibitor RBN-2397 in patients with selected advanced solid tumors
2023 · Timothy A. Yap, Andres Cervantes, et al. · Cancer Research · 2
Tumor-infiltrating Lymphocytes Expression in Stage IIIc/IV of High-grade Serous Ovarian Cancer: Variation with Neoadjuvant Chemotherapy and Prognostic Value
2019 · K Rojas, G Prado-Vazquez, et al. · Oncogen · 2
PDF
Representation of young adult(19–29 y) and elderly(>75 y) patients populations in an early drug development unit
2022 · M. Vieito Villar, K. Rojas, et al. · European Journal of Cancer · 1
PDF
Supplementary Material S1 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Table S1 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
Supplementary Figure S6 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Figure S9 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Figure S3 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Figure S8 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Figure S7 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Figure S2 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Figure S1 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Figure S5 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Figure S4 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Table S2 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
Data from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
34 (PB022): Phase I/II trial of RVU120, a CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors
2024 · J. Jedrzejewski, M. Blaszkowska, et al. · European Journal of Cancer
Works count: 30
Citation count: 147
H-index: 6
I10-index: 5
Year
Topic
Type